The value of MR diffusion-weighted imaging in the assessment of tumor response after TACE in patients with hepatocellular carcinoma

doi:10.3969/j.issn.1007-3969.2015.04.012

China Oncology ›› 2015, Vol. 25 ›› Issue (4): 311-315.doi: 10.3969/j.issn.1007-3969.2015.04.012

Previous Articles Next Articles

The value of MR diffusion-weighted imaging in the assessment of tumor response after TACE in patients with hepatocellular carcinoma

YANG Huan, LI Wentao, XU Lichao

Department of Interventional Therapy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Online:2015-04-30 Published:2015-05-25
Contact: 李文涛　E-mail:liwentao@126.com

Abstract

Abstract: Transcatheter arterial chemoembolization (TACE) is the main treatment method for advanced hepatocellular carcinoma (HCC). As a non-invasive functional MR imaging, diffusion weighted imaging (DWI) can reflect the functional changes in tumor before morphologic changes. In the follow-up of HCC after TACE, DWI can detect new lesions and distinguish necrotic neoplastic tissue and residual neoplastic tissue timely and accurately.

Key words: Hepatocellular carcinoma, Diffusion weighted imaging, Transcatheter arterial chemoembolization, Apparent diffusion coefficient, Follow-up

YANG Huan, LI Wentao, XU Lichao. The value of MR diffusion-weighted imaging in the assessment of tumor response after TACE in patients with hepatocellular carcinoma[J]. China Oncology, 2015, 25(4): 311-315.

[1]	XIAO Feng , XIAO Jingwen , SHAO Jianguo , CHEN Liyan , GU Chunyan . The expression of programmed death 1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma and its correlation with prognosis [J]. China Oncology, 2021, 31(5): 419-427.
[2]	NIU Na, LIN Yansong. Application and research progress of selective internal radiation therapy with ⁹⁰ Y microspheres in hepatocellular carcinoma [J]. China Oncology, 2021, 31(5): 428-434.
[3]	LIU Min , CHEN Tianliang , GUO Juan , YI Xue , GAO Hongquan , WU Jiacui , WANG Yuxiao . Protein kinase Cβ Ⅱ promotes invasion of hepatocellular carcinoma by modulating autocrine of IL-6 [J]. China Oncology, 2021, 31(4): 268-276.
[4]	ZHANG Jun , DONG Yuhua , YANG Ye , ZHANG Mengqi , HE Chang . A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma [J]. China Oncology, 2021, 31(4): 294-301.
[5]	ZHANG Xin , ZHOU Cheng , ZHOU Kaiqian , BAI Qianming , JIANG Dongxian , SUJIE Akesu , HOU Yingyong , WANG Zheng , JI Yuan . MET gene amplification and its prognostic role in sarcomatoid hepatocellular carcinoma [J]. China Oncology, 2020, 30(9): 641-649.
[6]	XU Shanshan , SONG Qinqin , WU Hongjiao , FU Ning , CHE Lingyu , JIN Min , LIU Chong , HAN Sugui , ZHANG Xuemei , ZHANG Zhi . Genetic variation in membrane cofactor protein CD46 rs1970530 affects the risk of hepatocellular carcinoma [J]. China Oncology, 2020, 30(9): 656-660.
[7]	FAN Bo , QI Pan , SU Jianzhi , WEI Shufei , ZHANG Xuan , ZHANG Aili . Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University [J]. China Oncology, 2020, 30(8): 620-625.
[8]	OUYANG Xiaochun , ZOU Yeqing , LI Yumei , DING Xiaobing . ARHGAP4 promotes growth of hepatocellular carcinoma cells by regulating HK2 expression [J]. China Oncology, 2020, 30(7): 481-487.
[9]	PI Sidie, ZHENG Xiaochuan, MAO Binli, CUI Jing, HU Yuan. SAMHD1 inhibits the proliferation of hepatocellular carcinoma by regulating the expression of p27 [J]. China Oncology, 2020, 30(7): 489-496.
[10]	DONG Baolong , HE Yu , CHEN Shiyong , WU Biao , GAO Peng , YANG Xiaojun . Expression of KIF21B in hepatocellular carcinoma and its clinical significance [J]. China Oncology, 2020, 30(5): 355-361.
[11]	MENG Qiuhua, TIAN Jing, QIN Yan, MENG Qiuxiao, DONG Min. The mechanism of protein tyrosine phosphatase receptor type delta affecting expression of PD-L1 in hepatocellular carcinoma via STAT3 pathway [J]. China Oncology, 2020, 30(4): 261-267.
[12]	LEI Haike , LIAO Zhongli , LI Xiaosheng , ZHOU Qi , ZHAO Yulan , HE Mei , CHEN Weiqing , ZHOU Hong , ZHANG Wei , WU Yongzhong . Survival of esophageal cancer patients and its related risk factors in Chongqing [J]. China Oncology, 2020, 30(2): 98-105.
[13]	YU Mei,MEI Qi,HAN Yingying,ZHAI Lingyun,SHA Hongfang,XU Xiangyong,NI Juan,CUI Jianwei,DING Hong . Value of contrast-enhanced ultrasound in monitoring liver cirrhotic and dysplastic nodules and early diagnosis of hepatocellular carcinomas [J]. China Oncology, 2019, 29(9): 709-714.
[14]	CHEN Yang,YANG Qingsong,LU Jianping . Differentiation of central gland prostate cancer from benign prostatic hyperplasia by using monoexponential and biexponential DWI models [J]. China Oncology, 2019, 29(8): 583-589.
[15]	MA Jiaqiang, CAO Chunmei, Shyamal Goswami, CHEN Qin, GAO qiang, ZHANG Xiaoming. Detection of ICOS⁺T cells by multiplex immunohistochemistry in tumor tissue and its clinical significance in hepatocellular carcinoma [J]. China Oncology, 2019, 29(5): 352-361.

The value of MR diffusion-weighted imaging in the assessment of tumor response after TACE in patients with hepatocellular carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments